An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
Pharmacology, Toxicology and Pharmaceutical Science
3
9%
Biochemistry, Genetics and Molecular Biology
1
3%
Nursing and Health Professions
1
3%
Sports and Recreations
1
3%
Other
0
0%
Unknown
20
63%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2021.
All research outputs
#16,858,973
of 27,790,740 outputs
Outputs from OncoImmunology
#1,216
of 2,230 outputs
Outputs of similar age
#212,413
of 445,890 outputs
Outputs of similar age from OncoImmunology
#14
of 40 outputs
Altmetric has tracked 27,790,740 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,230 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,890 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
